"The U.S. Food and Drug Administration announced today that injectable drugs used in total parenteral nutrition (TPN) in critical shortage will be imported into the United States and available to patients this week.
TPN is an intravenous"...
(Generic versions may still be available.)
THE SAFETY AND EFFECTIVENESS OF ENOXACIN IN PEDIATRIC PATIENTS AND ADOLESCENTS (UNDER THE AGE OF 18 YEARS), PREGNANT WOMEN, AND LACTATING WOMEN HAVE NOT BEEN ESTABLISHED. (See PRECAUTIONS : Pediatric Use, Pregnancy, and Nursing Mothers subsections .) Enoxacin has been shown to cause arthropathy in immature rats and dogs when given in oral doses approximately 1.5 and 3.8 times, respectively, the highest human clinical dose based on a mg/m 2 basis after a four-week dosage regimen. Gross and histopathological examination of the weight-bearing joints of the dogs revealed lesions of the cartilage. Other quinolones also produce erosions of cartilage of weight-bearing joints and other signs of arthropathy in immature animals of various species. (See ANIMAL PHARMACOLOGY . )
Convulsions and abnormal electroencephalograms have been reported in some patients receiving enoxacin. Increased intracranial pressure, and toxic psychoses have been reported in patients receiving drugs in this class. Quinolones may also cause central nervous system stimulation which may lead to: tremors, restlessness/agitation, nervousness/anxiety, lightheadedness, confusion, hallucinations, paranoia, depression, nightmares, insomnia, and, rarely, suicidal thoughts or acts. These reactions may occur following the first dose. If these reactions occur in patients receiving enoxacin, the drug should be discontinued and appropriate measures instituted. As with all quinolones, enoxacin should be used with caution in patients with known or suspected CNS disorder that may predispose to seizures or lower the seizure threshold (e.g. , severe cerebral arteriosclerosis, epilepsy) or in the presence of other risk factors that may predispose to seizures or lower the seizure threshold ( e.g., certain drug therapy, renal dysfunction). (See PRECAUTIONS : General , Information for Patients , Drug Interactions and ADVERSE REACTIONS .)
Serious and occasionally fatal hypersensitivity (anaphylactoid or anaphylactic) reactions, some following the first dose, have been reported in patients receiving quinolone therapy. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, tingling, pharyngeal or facial edema, dyspnea, urticaria, or itching. Only a few patients had a history of previous hypersensitivity reactions. Serious hypersensitivity reactions have also been reported following treatment with enoxacin. If an allergic reaction to enoxacin occurs, discontinue the drug. Serious acute hypersensitivity reactions may require immediate treatment with epinephrine. Oxygen, intravenous fluids, antihistamines, corticosteroids, pressor amines, and airway management, including intubation, should be administered as indicated.
Pseudomembranous colitis has been reported with nearly all antibacterial agents, including enoxacin, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents.
Treatment with broad-spectrum antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by Clostridium difficile is a primary cause of "antibiotic-associated colitis."
After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated.
Mild cases of pseudomembranous colitis usually respond to discontinuation of the drug alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial drug clinically effective against C. difficile colitis.
Ruptures of the shoulder, hand and Achilles tendons that required surgical repair or resulted in prolonged disability have been reported with fluoroquinolone antimicrobials. Enoxacin should be discontinued if the patient experiences pain, inflammation or rupture of a tendon. Patients should rest and refrain from exercise until the diagnosis of tendinitis or tendon rupture has been confidently excluded. Tendon rupture can occur at anytime during or after therapy with enoxacin.
Enoxacin has not been shown to be effective in the treatment of syphilis. Antimicrobial agents used in high doses for short periods of time to treat gonorrhea may mask or delay the symptoms of incubating syphilis. All patients with gonorrhea should have a serologic test for syphilis at the time of diagnosis. Patients treated with enoxacin should have a follow-up serologic test for syphilis after 3 months.
As with other quinolones, enoxacin should be used with caution in patients with a known or suspected CNS disorder that may predispose to seizures or lower the seizure threshold ( e.g., severe cerebral arteriosclerosis, epilepsy) or in the presence of other risk factors that may predispose to seizures or lower the seizure threshold ( e.g., certain drug therapy, renal dysfunction). (See WARNINGS and PRECAUTIONS : Drug Interactions .)
Moderate-to-severe phototoxicity reactions have been observed in patients exposed to direct sunlight while receiving enoxacin or some other drugs in this class. Excessive sunlight should be avoided. Therapy should be discontinued if phototoxicity occurs.
Ophthalmologic abnormalities, including cataracts and multiple punctate lenticular opacities, have been noted in patients undergoing treatment with enoxacin, as well as with some other quinolones, but have also been observed in patients receiving placebo in comparative trials. In clinical trials using multiple-dose therapy, ophthalmic tissue levels of enoxacin and other quinolones were significantly higher than respective plasma concentrations. The causal relationship, if any, of quinolones to lenticular abnormalities has not been established.
Decreased spermatogenesis and subsequent decreased fertility were noted in rats and dogs treated with doses of enoxacin that produced plasma levels in the animals three times higher than those produced in humans at the recommended therapeutic dosage. The potential for enoxacin to affect spermatogenesis in male patients is unknown.
Genetic toxicology tests included in vitro mutagenicity and cytogenetic assays and in vivo cytogenetic and micronucleus tests. Enoxacin did not induce point mutations in bacterial cells or mitotic gene conversion in yeast cells, with or without metabolic activation. Enoxacin did not induce sister chromatid exchanges or structural chromosomal aberrations in mammalian cells in vitro, with or without metabolic activation. In addition, enoxacin did not induce chromosomal aberrations in mice.
There was a minimal, dose-related, statistically significant increase in micronuclei at high doses in mice. The significance of these findings, in the absence of effects in other test systems, is not established.
Enoxacin produced no consistent effects on fertility and reproductive parameters in female rats given oral doses of enoxacin at levels up to 1000 mg/kg. Decreased spermatogenesis and subsequent impaired fertility was noted in male rats given oral doses of 1000 mg/kg. This dose is approximately 13-fold greater than the highest human clinical daily oral dose of 16 mg/kg, assuming a 50 kg person and based on a mg/m 2 basis.
Pregnancy: Teratogenic effects. Pregnancy Category C. Studies with enoxacin given orally to mice and rats have shown no evidence of teratogenic potential. The intravenous infusion of enoxacin into pregnant rabbits at doses of 10 to 50 mg/kg caused dose-related maternal toxicity (venous irritation, body weight loss, and reduced food intake) and, at 50 mg/kg, fetal toxicity (increased post-implantation loss and stunted fetuses).
At 50 mg/kg, the incidence of fetal malformations was significantly increased in the presence of overt maternal and fetal toxicity. There are no adequate and well-controlled studies in pregnant women. Enoxacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. (See WARNINGS.)
Nursing Mothers: It is not known whether enoxacin is excreted in human milk. Enoxacin is excreted in the milk of lactating rats. Because drugs of this class are excreted in human milk and because of the potential for serious adverse reactions from enoxacin in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Pediatric Use: Safety and effectiveness in pediatric patients and adolescents below the age of 18 years have not been established. Enoxacin causes arthropathy in juvenile animals. (See WARNINGS and ANIMAL PHARMACOLOGY . )
Geriatric Use: In multiple-dose clinical trials of enoxacin, elderly patients ( ≥65 years of age) experienced significantly more overall adverse events than patients under 65 years of age. However, the incidence of drug-related adverse reactions was comparable between age groups.
In elderly patients, the mean peak enoxacin plasma concentration was 50% higher than that in young adult volunteers receiving comparable single doses of enoxacin. (See CLINCAL PHARMACOLOGY.) Enoxacin is known to be excreted by the kidney and the risk of adverse reactions may be greater in patients with impaired renal function. The dosage should be reduced in patients with renal impairment. (See DOSAGE AND ADMINISTRATION.)
Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Penetrex Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.